Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study

被引：1

作者：

Zhang, Dongming ^{[1
]}

Liu, Xiaoyan ^{[1
]}

Shen, Fangfang ^{[2
]}

Zhao, Dahai ^{[3
]}

Shi, Yuequan ^{[1
]}

Zhang, Haoran ^{[1
]}

Liu, Jia ^{[1
]}

Gao, Xiaoxing ^{[1
]}

Chen, Minjiang ^{[1
]}

Zhao, Jing ^{[1
]}

Zhong, Wei ^{[1
]}

Gao, Junzhen ^{[4
]}

He, Min ^{[5
]}

Liu, Yonggang ^{[6
]}

Yang, Xiaoling ^{[7
]}

Qin, Jianwen ^{[8
]}

Tang, Yuling ^{[9
]}

Mu, Xinlin ^{[10
]}

Gu, Yangchun ^{[11
]}

Zhang, Shucai ^{[12
]}

Chen, Xueqin ^{[13
]}

Pang, Li ^{[14
]}

Meng, Qingwei ^{[15
]}

Guo, Ye ^{[16
]}

Zhang, Yuhui ^{[17
]}

Li, Wei ^{[18
]}

Xing, Puyuan ^{[19
]}

Cheng, Yuan ^{[20
]}

Xin, Tao ^{[21
]}

Li, Qingxia ^{[22
]}

Li, Yu ^{[23
]}

Chen, Jun ^{[24
]}

Gao, Feng ^{[25
]}

Jin, Bo ^{[26
]}

Rossi, Antonio ^{[27
]}

Adachi, Hiroyuki ^{[28
]}

Guerrera, Francesco ^{[29
,30
]}

Husain, Hatim ^{[31
]}

Xu, Yan ^{[1
]}

Wang, Mengzhao ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[2] Shanxi Med Univ, Shanxi Prov Canc Hosp, Canc Hosp, Dept Resp Med, Taiyuan, Peoples R China

[3] Anhui Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hefei, Peoples R China

[4] Inner Mongolia Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp, Hohhot, Inner Mongolia, Peoples R China

[5] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Oncol, Hohhot, Inner Mongolia, Peoples R China

[6] Baotou Canc Hosp, Dept Thorac Oncol, Baotou, Inner Mongolia, Peoples R China

[7] Shanxi Med Univ, Shanxi Bethune Hosp, Dept Thorac Oncol, Hosp 3, Taiyuan, Peoples R China

[8] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China

[9] First Hosp Changsha, Resp Med Ctr, Changsha, Peoples R China

[10] Peking Univ, Dept Resp & Crit Care Med, Peoples Hosp, Beijing, Peoples R China

[11] Peking Univ, Dept Med Oncol & Radiat Sickness, Hosp 3, Beijing, Peoples R China

[12] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China

[13] Zhejiang Univ, Hangzhou Canc Hosp, Sch Med, Dept Thorac Oncol, Hangzhou, Peoples R China

[14] Capital Med Univ, Beijing Shijitan Hosp, Dept Resp & Crit Care, Beijing, Peoples R China

[15] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China

[16] First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China

[17] Capital Med Univ, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[18] Bengbu Med Coll, Dept Resp & Crit Care Med, Affiliated Hosp 1, Bengbu, Peoples R China

[19] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China

[20] Peking Univ First Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[21] Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, Harbin, Peoples R China

[22] Hebei Gen Hosp, Dept Oncol, Shijiazhuang, Peoples R China

[23] Shandong Univ, Dept Resp Med, Qilu Hosp, Jinan, Peoples R China

[24] Tianjin Med Univ, Tianjin Lung Canc Inst, Dept Lung Canc Surg, Gen Hosp, Tianjin, Peoples R China

[25] Beidahuang Ind Grp, Gen Hosp, Dept Oncol, Harbin, Peoples R China

[26] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[27] IQVIA, Oncol Ctr Excellence, Therapeut Sci & Strategy Unit, Milan, Italy

[28] Kanagawa Canc Ctr, Dept Thorac Surg, Yokohama, Japan

[29] Univ Torino, Dept Surg Sci, Turin, Italy

[30] Azienda Osped Univ Citta Salute & Sci Torino, Dept Thorac Surg, Turin, Italy

[31] Univ Calif San Diego, Dept Med, La Jolla, CA USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 11期

关键词：

Osimertinib; comparator epidermal growth factor receptor tyrosine kinase inhibitor (comparator EGFR-TKI); propensity score matching (PSM); real-world study; OPEN-LABEL; FAMILY-HISTORY; SURVIVAL-DATA; PHASE-III; MUTATIONS; GEFITINIB; ADENOCARCINOMA; CHEMOTHERAPY; RESISTANCE; ERLOTINIB;

D O I：

10.21037/tlcr-23-577

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the phase 3 FLAURA trial, osimertinib was compared with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line treatment for EGFR-mutant survival (OS), and a similar safety profile. However, more studies demonstrating the effectiveness and safety of osimertinib as a first-line strategy are needed in real-world populations. Methods: We enrolled 1,556 patients with EGFR-mutated stage IIIc-IV NSCLC from the CAPTRA-Lung database. All patients received either osimertinib (n=202) or a first-generation EGFR-TKI (n=1,354) as their initial treatment. To adjust for differences in baseline characteristics between two groups, 1:2 propensity mutations, and central nervous system (CNS) metastases. The standardized mean differences (SMD) before and after PSM were calculated to examine the balance of covariate distributions between two groups. Results: After PSM, 202 patients receiving osimertinib and 404 patients receiving first-generation 19.4 months [95% confidence interval (CI): 14.3-24.4] in the osimertinib arm and 10.9 months (95% CI: profile to that of comparator EGFR-TKIs when used as a first-line strategy in NSCLC patients.

引用

页码：2229 / +

页数：18

共 50 条

[1] Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: A Chinese, multicenter, real-world cohort study
Zhang, D.
Liu, X.
Shen, F.
Zhao, D.
Shi, Y.
Zhang, H.
Liu, J.
Gao, X.
Chen, M.
Zhao, J.
Zhong, W.
Xu, Y.
Wang, M.
ANNALS OF ONCOLOGY, 2023, 34
[2] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
Jeong, Byeong-Ho
Um, Sang-Won
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
[3] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
Moriya, Tetsuji
Hamaji, Masatsugu
Yoshizawa, Akihiko
Miyata, Ryo
Noguchi, Misa
Tamari, Shigeyuki
Chiba, Naohisa
Miyamoto, Hideaki
Toyazaki, Toshiya
Tanaka, Satona
Yamada, Yoshito
Yutaka, Yojiro
Nakajima, Daisuke
Ohsumi, Akihiro
Menju, Toshi
Date, Hiroshi
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
[4] Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Gray, Jhanelle E.
Okamoto, Isamu
Sriuranpong, Virote
Vansteenkiste, Johan
Imamura, Fumio
Lee, Jong Seok
Pang, Yong-Kek
Cobo, Manuel
Kasahara, Kazuo
Cheng, Ying
Nogami, Naoyuki
Cho, Eun Kyung
Su, Wu Chou
Zhang, Guili
Huang, Xiangning
Li-Sucholeiki, Xiaocheng
Lentrichia, Brian
Dearden, Simon
Jenkins, Suzanne
Saggese, Matilde
Rukazenkov, Yuri
Ramalingam, Suresh S.
CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6644 - 6652
[5] Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
Xu, Ziyi
Hao, Xuezhi
Wang, Qi
Wang, Jing
Yang, Ke
Wang, Shouzheng
Teng, Fei
Li, Junling
Xing, Puyuan
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 863 - 873
[6] Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting
Apple, Jon
Shenolikar, Rahul
De Silva, Kevin
Sun, Ping
Spira, Alexander
CANCER MEDICINE, 2023, 12 (12): : 13415 - 13425
[7] Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.
Simmons, Daniel
DerSarkissian, Maral
Shenolikar, Rahul
Wang, Min-Jung
Lax, Angela
Muthukumar, Aruna
Laliberte, Francois
Duh, Mei Sheng
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.
Simmons, Daniel
DerSarkissian, Maral
Shenolikar, Rahul
Wang, Min-Jung
Lax, Angela
Muthukumar, Aruna
Laliberte, Francois
Duh, Mei Sheng
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
[9] First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation - Positive non-small cell lung cancer patients
Sequist, Lecia V.
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S143 - S145
[10] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
Nieva, J.
Taylor, A.
Servidio, L.
Sun, P.
Okhuoya, P.
Horvat, P.
Tolani, E.
Magee, K.
Mathur, R.
Balakrishna, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113

← 1 2 3 4 5 →